Two phase II clinical trials (Table 2) are currently underway to test FAK inhibitor GSK2256098 and AZD2014 in patients with NF2-mutated meningiomas and NF2 patients with symptomatic meningiomas respectively (19, 20). This evidence concerns the gene PTK2 and meningioma.